14 February 2023
Benchmark Holdings plc
("Benchmark", the "Company" or the "Group")
Notice of Q1 Results
Presentation for analysts and institutional investors
Benchmark Holdings plc (AIM: BMK, Euronext Growth Oslo: BMK), the aquaculture biotechnology business, will announce its Q1 results, for the three month period ended 31 December 2022, on Tuesday 28 February 2023.
Presentation for analysts and investors at 9 am CET
Trond Williksen, Chief Executive Officer and Septima Maguire, Chief Financial Officer will host an in-person presentation for analysts and institutional investors on the day at 9.00 am CET/8.00 am UK time in Oslo, Norway. The presentation will take place at Hotel Continental, Stortingsgata 24/26, 0117 Oslo.
A live webcast of the presentation is available for analysts and investors to join remotely at the following link: https://channel.royalcast.com/hegnarmedia/#!/hegnarmedia/20230228_7
For further details, and to register your interest, please contact benchmark@mhpgroup.com.
Equity Development webcast on Wednesday 1 March at 12 pm UK time
Trond Williksen, Chief Executive Officer and Septima Maguire, Chief Financial Officer will host a second webcast for retail investors and wealth managers on Wednesday 1 March at 13.00 pm CET/12.00 pm UK time. The webcast is open to all existing and potential shareholders.
To register please visit: https://www.equitydevelopment.co.uk/news-and-events/benchmark-q1results-presentation-1march2023
A recording of the presentation will be available after the event on the Equity Development website.
Enquiries
|
|
About Benchmark
Benchmark is a leading aquaculture biotechnology company. Benchmark's mission is to enable aquaculture producers to improve their sustainability and profitability.
We bring together biology and technology to develop innovative products and solutions which improve yield, quality and animal health and welfare for our customers. We do this by improving the genetic make-up, health and nutrition of their stock - from broodstock and hatchery through to nursery and grow out.
Benchmark has a broad portfolio of products and solutions, including salmon eggs, live feed (Artemia), specialist diets and probiotics and sea lice treatments. Find out more at www.benchmarkplc.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
